No. Specialised clinical AI, general productivity tools and clinical reference tools may all be used by the same workforce, but they should not be governed the same way. Risk depends on the data, the user intent and the workflow. A useful policy distinguishes between tools built for ePHI and tools that should never receive it.
Different AI tools create different compliance obligations
Healthcare compliance should follow the function and data path of the tool, not the marketing label. A model embedded in a diagnostic workflow, a browser-based productivity assistant and a clinical reference search tool can all carry different obligations because they touch different data classes, users and decision points. The practical question is whether the tool can see, generate, store or transmit ePHI, and whether its outputs can influence patient care.
That distinction matters because a single workforce may use several AI tools under different controls. A decision-support tool that reaches into clinical records needs tighter review than a drafting assistant that is barred from patient data. A reference tool may also be lower risk if it is read-only and cannot retain prompts, but it still needs review for provenance, output quality and whether it can be used in ways that drift into clinical advice.
Healthcare organisations that want a clearer baseline can anchor their policy work in the AI Governance Guide, which is useful for setting risk tiers, use case registers and oversight roles before tools are approved.
Why the same workforce can create very different AI risk profiles
The same clinician, analyst or admin user can interact with tools that sit in very different trust zones. One tool may be approved for summarising internal text, another may be connected to patient data, and a third may be a public-facing reference service that should never receive regulated data. Treating them the same creates blind spots, because the main control question changes from “Can staff use AI?” to “What data, authority and workflow does this tool actually touch?”
Tool type also changes the harm profile. A general productivity tool can still create compliance exposure if users paste ePHI into it or if retention settings are unclear. A clinical AI tool may have stronger procurement and validation requirements because its outputs can influence diagnosis, treatment planning or documentation quality. In both cases, the control objective is to keep data handling, output use and escalation boundaries explicit.
For healthcare organisations trying to separate ordinary productivity use from higher-risk clinical workflows, the AI Acceptable Use Policy Template is a practical starting point because it distinguishes approved tools, prohibited data use and human review expectations.
Third-party services deserve separate scrutiny when they process healthcare data or sit inside clinical workflows. The Third-Party AI Risk Guide is relevant when the key question is how vendor terms, retention, monitoring and downstream obligations change the compliance posture of an external AI service.
How to classify AI tools for compliance without overcomplicating the policy
A workable classification scheme usually starts with three questions: what data the tool can access, what the user is allowed to do with its output, and whether the tool can affect clinical, operational or administrative decisions. Those answers are usually more important than whether the tool is labelled “AI,” “copilot,” “assistant” or “automation.” The policy should also separate tools that are never allowed to receive ePHI from tools that may process it under explicit governance.
That classification should be paired with review cadence. Higher-risk tools need stronger onboarding, documented purpose, testing, vendor review and periodic reassessment. Lower-risk tools still need usage rules, but the evidence burden should be lighter. The mistake to avoid is one universal approval path that is too strict for harmless tools and too weak for tools that handle patient data or affect care decisions.
The compliance discipline is easier to sustain when organisations build a living inventory and risk tiering process. The AI Risk Assessment Guide helps operationalise that separation by scoping use cases, rating risk and revisiting the assessment when the workflow changes.
Risk and Threat Considerations
Healthcare AI risk is not uniform because the most serious failures usually come from data leakage, overbroad access or users treating outputs as clinically authoritative. A general tool that should never receive ePHI becomes a compliance problem the moment staff paste patient content into it, while a clinical tool becomes more sensitive if its output can influence care without adequate review.
Failure mechanism: Users move regulated data into a tool that was not approved for that data, or they rely on a tool’s output as if it were validated clinical content when it is only assistive.
Impact: The organisation can create privacy, recordkeeping and clinical-safety exposure at the same time, especially if retention, vendor reuse or downstream sharing is not clearly controlled.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST AI RMF and NIST SP 800-53 Rev 5 set the technical controls, while ISO/IEC 27001:2022 and GDPR define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST AI RMF | GV.1 — Govern | AI use needs governance, risk tiers and oversight for healthcare workflows. |
| Recommendation — Define AI governance roles, risk tiers and review cadence for healthcare use cases. | ||
| NIST SP 800-53 Rev 5 | RA-3 — Risk Assessment | Healthcare AI tools need risk assessment based on data access, use and impact. |
| AC-6 — Least Privilege | Tool access should be limited to the minimum data and actions needed in care workflows. | |
| Recommendation — Assess each AI tool’s data exposure, workflow impact and approval conditions. Restrict each AI tool to the minimum data and actions required for its role. | ||
| ISO/IEC 27001:2022 | A.5.15 — Access control | Different AI tools require different access rules and approval boundaries. |
| Recommendation — Set tool-specific access rules that reflect the data each AI system may handle. | ||
| GDPR | Article 32 — Security of processing | If AI tools process personal health data, security controls must match the processing risk. |
| Recommendation — Apply security measures proportionate to the personal data each AI tool processes. | ||
Practitioner Guidance
What to prioritise: Start by splitting tools into three buckets, ePHI-capable clinical tools, limited-purpose productivity tools and reference-only tools, then apply different approval and monitoring requirements to each bucket.
What to verify: Confirm whether the vendor retains prompts or outputs, whether the tool is trained or fine-tuned on submitted data, and whether users can bypass intended restrictions by copy-pasting clinical material into a general tool.
Decision rule: If a tool can receive ePHI or influence patient care, treat it as a governed system with explicit approval and documented use boundaries; if it cannot do either, keep the control set lighter but still enforce no-ePHI usage.
Practitioner takeaway: The right compliance model is not “AI yes or no,” but “what data, authority and workflow does this specific tool touch, and how much harm can it cause if it is misused?”
Related resources from NHI Mgmt Group
- When should organisations treat an NHI as a high-priority risk?
- How should healthcare organisations structure a risk management programme that covers clinical, operational, compliance, and cybersecurity risks at the same time?
- Should organisations treat generative AI tools as third-party risk when deciding where to allow them in the business?
- Should organisations treat AI code generators as developer tools or software supply chain risk?